Vimarsana
Biggest News Aggregation in the World

Page 4 - Clinical Laboratory Evaluation Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Laboratory Evaluation Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Laboratory Evaluation Program Today - Breaking & Trending Today

Foundation Medicine and Natera Announce Broad Clinical Launch and Medicare Coverage of FoundationOneTracker - Vimarsana News

Foundation Medicine and Natera Announce Broad Clinical Launch and Medicare Coverage of FoundationOneTracker

CAMBRIDGE - Foundation Medicine, Inc., and Natera, Inc., today announced the broad clinical launch of FoundationOneTracker, a personalized tissue-informed circulating tumor DNA test to monitor...

Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2023 Earnings Call Transcript - Vimarsana News

Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2023 Earnings Call Transcript

Operator: Good afternoon, and welcome to the Applied DNA Sciences' First Quarter Fiscal 2023 Financial Results Conference Call. All participants will be in a listen-only mode.

New York approves AI-driven breast cancer diagnostic - Vimarsana News

New York approves AI-driven breast cancer diagnostic

The state's health department has approved the PreciseDx Breast Test lab test which uses artificial intelligence to improve cancer grading and risk categorization

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting - Vimarsana News

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

05.12.2022 - SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing ...

Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers - Vimarsana News

Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers

Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers - read this article along with other careers information, tips and advice on BioSpace